Stifel analyst Paul Matteis reiterated a Buy rating and $444.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY)

The analyst commented, "We're reiterating our Buy rating on ALNY following its TTR investor event, which marks one-year of Amvuttra's approval in ATTR-CM. The event highlighted management's conviction in maintaining a strong launch trajectory for their flagship product, regardless of the outcome of catalysts over the next 12-36mos (i.e., IONS/AZN's eplontersen CVOT readout 2H26 and potential launch, tafamidis LOE in 2028) that will have broader implications on the ATTR space. Further, ALNY shared the latest details on early launch metrics, all of which point to vutri gaining significant traction in the category in a very short time frame. Taking a step back, the stock has traded down meaningfully this year (alongside other high-quality growth names in biotech [ARGX, INSM]), partly attributed to ALNY missing consensus in 4Q and ahead of anticipated 1Q dynamics (fewer product shipping weeks). It may take a few quarters--but we remain positively biased after the pullback."

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $308.05 yesterday.